for the National Heart, Lung, and Blood Institute Exome Sequencing Project IMPORTANCE Stroke is the second leading cause of death and the third leading cause of years of life lost. Genetic factors contribute to stroke prevalence, and candidate gene and genome-wide association studies (GWAS) have identified variants associated with ischemic stroke risk. These variants often have small effects without obvious biological significance. Exome sequencing may discover predicted protein-altering variants with a potentially large effect on ischemic stroke risk.
the overt symptomatic manifestation of brain infarction, but the burden of cerebrovascular disease is much greater, with many more covert infarctions not resulting in the diagnosis of clinical stroke. More than 7% of asymptomatic adults in the general population have radiographic evidence of brain infarction, 3 with substantially higher rates in the elderly population. 4 Although many effective treatments for stroke exist, novel strategies for stroke prediction, prevention, and therapy need to be found. Epidemiologic and family studies 5, 6 support an inherited component to stroke risk. Family-based linkage studies, including Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy and Cerebral Autosomal Recessive Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, 7 identified rare forms of stroke. Ischemic stroke studies include large candidate gene association meta-analyses, 8, 9 mendelian randomization, 10 studies of affected sibpair families, 11 and genome-wide association studies (GWAS). [12] [13] [14] The joint International Stroke Genetics Consortium/Wellcome Trust Case Control Consortium 2 (WTCCC2) effort 14 identified HDAC9 (7p21.1; GenBank NM_058176) and confirmed associations of ischemic stroke with variants in PITX2 (GenBank KJ891816) and ZFHX3 (GenBank NM _006885) (cardioembolic stroke) and in 9p21 (large-vessel/ atherosclerotic stroke). The Australian Stroke Genetics Collaborative, the WTCCC2, and the International Stroke Genetics Consortium have identified and replicated the chromosome 6p21.1 large-artery susceptibility locus. 13 Discovering the missing heritability for ischemic stroke could provide critical insights into the cause of the disease, novel pathways, and therapeutic targets. 15 Rare, protein-coding variation could contribute a burden of risk for ischemic stroke, attributable to multiple variants in a gene rather than any individual variant. 16, 17 Exome sequencing in ischemic stroke has been performed only as a pilot study. 18 Herein, we present results from what we believe to be the first large-scale study of protein-coding region variants in ischemic stroke from the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP). We describe analyses used to identify novel stroke susceptibility genes, determine genes and variants that are specific to stroke subtypes, and establish replication of previous GWAS and candidate gene associations.
Methods

Participating Studies and Design
The Table 1 . Discovery analysis by exome sequencing focused on smallvessel and large-vessel subtypes in unrelated persons of European ancestry. Replication was conducted in small-and large-vessel subtypes in SWISS and ESP African American individuals, as well as ExomeChip data from European American participants in the WHI that included cardioembolic subtypes. Exome sequencing was performed on 365 unrelated cases (327 cases from NHLBI cohorts and 38 cases from ISGS: 114 with large-vessel subtype, 249 with small-vessel subtype, and 2 undetermined), 47 affected sibpairs from SWISS (94 individuals, used in replication: 28 pairs concordant for smallvessel subtype and 19 pairs concordant for large-vessel subtype), and African Americans (83 cases and 317 controls, used in replication). ExomeChip genotyping was performed on 1672 unrelated WHI ischemic stroke cases: 107 with large-vessel subtype, 224 with small-vessel subtype, 605 with cardioembolic subtype, and 736 of undetermined subtype. Cases classified as undetermined were included in the overall case-control analysis but not the subtype-specific analyses. Controls (n = 809) were identified as participants with exome sequence data who had not experienced a stroke or myocardial infarction at baseline or on subsequent follow-up and as individuals who were originally ascertained on the basis of low blood pressure or decreased low-density lipoprotein choles- 
Genetic Data
Exome sequencing was performed at the Broad Institute and the University of Washington (eAppendix 2 in the Supplement). ExomeChip genotyping was performed at the Broad Institute (eAppendix 3 in the Supplement). The ESP exome sequencing and ExomeChip genotyping started on January 1, 2010, and continued through June 30, 2012. Analyses were conducted on the full data set between July 12, 2012, and July 13, 2013. A total of 225 239 protein-coding variants were common to both ESP exome sequencing and ExomeChip genotyping, of which 119 963 were polymorphic in the full ESP sample (n = 7355). The self-reported ancestry and genetic ancestry distributions by principal components analysis are shown in eFigure 1 in the Supplement.
Statistical Analysis
Single-variant tests and 2 gene-based tests were used to determine the association with ischemic stroke, conditional on the minor allele frequency (MAF) of individual variants (eAppendix 4 in the Supplement). Variants with MAF of 0.5% or more and at least 100 observations with a nonmissing genotype were analyzed using a single-variant test. For genebased tests, only missense, splice, or nonsense variants were considered. Variants with MAF of 5% or less were analyzed with the sequence kernel association test (SKAT), 20 or variants with MAF of 1% or less analyzed with the combined multivariate and collapsing method, using variants with MAF of less than 1% (CMC/T1 test). 21 For SKAT and CMC/T1, only genes with cumulative MAF of 0.5% or more were assessed. Analyses were conducted separately for exome sequence (combining data from all cohorts and ISGS) and ExomeChip (WHI) data; a metaanalysis was conduc ted using seqMeta software (http://cran.r-project.org/web/packages/seqMeta/ . In the discovery phase, these analyses were conducted for all ischemic stroke, small-vessel subtype, and large-vessel subtype. Affected sibpairs from SWISS were analyzed using identity-by-descent methods (eAppendix 4 in the Supplement). Regions of excess identity by descent were examined, focusing on missense, nonsense, stopgain/loss functional variants. Single-variant and aggregate identity-by-descent probabilities of each gene across all available sibpairs were calculated to generate logarithm-of-theodds scores for excess identity-by-descent sharing, adjusting for local recombination rates based on European ancestry estimates (HapMap phase 3), repeated for sibpairs concordant for small-vessel and large-vessel subtypes. The distribution of scores from the identity-by-descent analyses is shown in eFigure 2 in the Supplement.
Targeted secondary analysis of 59 candidate genes previously associated with ischemic stroke, stroke risk factors, and mendelian syndromes yielded 134 variants. Most of these variants are not located in protein-coding regions; however, proxies were identified with strong linkage disequilibrium with ESPdefined protein-coding variants. For single-variant tests, significance was defined as P < 1.86 × 10 −4 . For gene-based tests, 33 genes contained polymorphic variants for analysis and significance was defined as P < 7.58 × 10 −4 since 2 genebased tests (CMC/T1 and SKAT) were used.
Results
Exome Variants Associated With Ischemic Stroke
Single-variant tests identified 2 protein-coding variants significantly associated with ischemic stroke ( ). Although not reaching exomewide significance, a common (MAF, 0.379) variant, rs5001076, in PRIM2 (primase, DNA, polypeptide 2 [58 kilodaltons (kDa)]); 6p11.2; GenBank NM_000947) showed evidence of increased risk with ischemic stroke (OR, 2.11; P = 2.96 × 10 −6 ) ( Table 2 ).
Rare and infrequent protein-coding variants in PDE4DIP from exome sequencing in 365 cases and 809 controls and their estimated effect on ischemic stroke risk are shown in the Figure. The results of no single-variant or gene-based test attained statistical significance for the small-vessel (lacunar) stroke subtype ( Table 3) . PDE4DIP rs1778155 had direction and size of effect on risk consistent in the all-stroke and small-vessel stroke categories (OR, 2.03; meta-analysis P = 7.96 × 10 −6 ). ACOT4 rs35724886 also had the same direction and similar size of effect on risk (OR, 1.95; meta-analysis Cases of cardioembolic ischemic stroke were not selected for ESP exome sequencing; these participants were sequenced only if they were selected for other (nonstroke) phenotypes or were included later for ExomeChip genotyping. No statistically significant associations with cardioembolic stroke were found by either single-variant or gene-based tests. The most significant single-variant association was with PPIP5K2 rs35671301 (GenBank NM_001276277) (diphosphoinositol pentakisphosphate kinase 2; 5q21.1; OR, 3.59; MAF, 0.011; metaanalysis P = 1.01 × 10 −5 ). The SKAT test also provided support for PPIP5K2 on risk in the cardioembolic stroke (5 variants with cumulative MAF, 0.104; meta-analysis P = 1.51 × 10 −5 ).
Replication of Exome Variants Associated With Ischemic Stroke
Single-nucleotide polymorphisms in PDE4DIP and ACOT4 were analyzed in an independent set of affected sibpairs from SWISS and unrelated ESP African American participants. The PDE4DIP rs1778155 variant had significantly increased allele sharing identity by descent (P = 1.16 × 10 −4 ) and was observed in 16 of 19 large-vessel concordant pairs with a logarithm of the odds of 6.07 (OR, 2.41; MAF, 0.302; P = 2.18 × 10 −5 ) and a false discovery rate of P = 6.39 × 10 −3 .
ACOT4 rs35724886 was not polymorphic in either the SWISS or WHI ExomeChip data. A significant association with ischemic stroke was observed for PDE4DIP rs1778155 in the ESP African American samples (MAF, 0.191; OR, 2.34, P = 7.50 × 10 −4 ). This variant failed genotype quality control metrics on the ExomeChip and was not analyzed. In African Americans, no significant association was detected for ) and in both subtypes (small-vessel meta-analysis P = .008; large-vessel meta-analysis P = .02). Variants in ZFHX3 (zinc finger homeobox 3; 16q22.3), a candidate gene for atrial fibrillation, were nominally associated with all ischemic stroke using the CMC/T1 test (P = .001), primarily in the cardioembolic subtype (P = .04). Results for all candidate genes are presented in eTables 1 through 4 in the Supplement.
Discussion
We report the results of ESP exome sequencing and ExomeChip genotyping of 2037 cases of ischemic stroke and 5318 controls, with replication in an African American population and a collection of affected sibpairs. We present evidence supporting the role of protein-coding variants in 2 novel genes, PDE4DIP and ACOT4, which are associated with an increased risk of ischemic stroke. We evaluated protein-coding variants in previously reported genes associated with ischemic stroke, and support the role of ABCA1 in large-vessel stroke and ZFHX3 in cardioembolic stroke.
A primary interacting partner of PDE4DIP is PDE4D (phosphodiesterase 4D, cAMP-specific; GenBank NM_001104631), originally identified as linked to ischemic stroke in Icelandic families. 24 The PDE4D variants have been extensively studied 25-28 for association with ischemic stroke risk in diverse populations, with equivocal results. A meta-analysis 29 of ischemic stroke was conducted on 7 studies, using approximately 12 000 cases and 15 000 controls that included 6 singlenucleotide polymorphisms in PDE4D. In the meta-analysis, PDE4D rs702553 had a significant association with ischemic stroke. The PDE4D result, coupled with PDE4DIP identified in the present study, 30,31 supports a role of this pathway in ischemic stroke. The ACOT4 gene encodes an enzyme that catalyzes the hydrolysis of acyl-coenzyme A (CoA) to the free fatty acid and coenzyme A, regulating intracellular levels of acyl-CoA and fatty acids. Selected fatty acids are associated with adverse outcomes including dyslipidemia, inflammation, myocardial infarction, and other cardiovascular mortality.
32-36
Human ACOT4 hydrolyzes succinyl-CoA, glutaryl-CoA, and long-chain acyl-CoA reactions catalyzed by multiple enzymes in other species. Expression of ACOT4 is regulated by peroxisome proliferator-activated receptor-α, 37,38 a nuclear receptor that has been implicated in vascular and cardiac disease and represents a therapeutic target in diabetes mellitus. 39 ACOT4 links risk for ischemic stroke with fatty acid metabolism.
This study, which we believe to be the largest on exome sequencing in stroke, has limitations. The replication of PDE4DIP rs1778155 association with ischemic stroke succeeded in both affected sibpair families and a small casecontrol cohort of African ancestry; however, it was not replicated in ExomeChip analyses. Furthermore, the ACOT4 rs35724886 infrequent variant was not informative in the replication samples and, therefore, was not replicated. Because these are protein-coding variants, their coverage in GWAS reports ( ). However, ACOT4 rs35724886 is only 1.4 Mb from the METASTROKE-identified RGS6 (regulator of G-protein signaling 6; 14q24.2; GenBank NM _001204416) rs2238238 variant (intronic, associated with all ischemic stroke: OR, 1.18; P = 1.65 × 10 −6 ). Thus, META-STROKE provides indirect support for the ACOT4 contribution to ischemic stroke. Several candidate genes and loci were not analyzed, since few protein-coding variants were identified through ESP exome sequencing or included on the ExomeChip (eg, HDAC9, PDE4D). The 9p21.3 region, previously associated with large-vessel ischemic stroke, contains few protein-coding genes and, therefore, few coding-region variants. Only 3 variants in CDKN2A (cyclin-dependent kinase inhibitor 2A; GenBank NG_007485) and 1 variant in CDKN2B-AS1 (CDKIN2B-antisense RNA 1; GenBank HG975381) were analyzed, with no variant associated with overall ischemic stroke or stroke subtype. Finally, our discovery sample focused on small-and large-vessel ischemic stroke subtypes to increase statistical power to detect novel genetic loci and reduce heterogeneity. Subsequent epidemiologically robust sampling approaches, consistent with the underlying distribution of subtypes in the population, should be conducted. Such studies would enable estimation of risk attributable to these genes (eg, PDE4DIP and ACOT4) and pathways to smalland large-vessel stroke and the effect of these variants in individual risk profiles for ischemic stroke. The NHLBI ESP is the first large-scale exome sequencing project to focus on complex human phenotypes rather than mendelian disorders. Although data from both European Americans and African Americans were sequenced in the ESP, only European Americans had sufficiently large numbers of ischemic stroke to permit robust genetic analyses. The motivation for exploring the exome was that the protein-coding region variants would have greater likelihood of functional impact and, therefore, larger effects on disease risk, although examples of this remain few and require large sample sizes, similar to those of GWAS. Nevertheless, exome sequencing has, as exhibited in the present study, provided novel gene targets and biological pathways for examination on their role in ischemic stroke.
